Nifty Pharma News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Alkem Laboratories Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Alkem Laboratories Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news and updates on Nifty Pharma from all sources in a single place.

Load latest

Alkem Laboratories Ltd.

19 Sep 2025

5495.00

-0.84%

CXO 1x1: Dr. Vikas Gupta, CEO

Buy: Alkem Laboratories Ltd.

Target

ICICI Securities Limited

Alkem Laboratories’ CEO, Dr. Vikas Gupta, is targeting double-digit revenue growth in the medium term, driven by strong hold in India (68% of sales), other international markets and new ventures.

Alkem Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

18 Sep 2025

1301.40

-1.54%

Company Update

Dr Reddys Laboratories Ltd - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

BSE India

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

pdf

Sun Pharmaceutical Industries Ltd.

18 Sep 2025

1644.00

-0.72%

Company Update

Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - …

BSE India

Intimation of the Schedule of Analyst Meeting

pdf

Torrent Pharmaceuticals Ltd.

18 Sep 2025

3655.90

0.74%

Company Update

Torrent Pharmaceuticals Ltd - 500420 - Redemption Of Commercial Papers Issued Under ISIN: INE685A14146

BSE India

Redemption of Commercial papers issued under ISIN: INE685A14146

pdf

Natco Pharma Ltd.

18 Sep 2025

864.50

-2.23%

Natco Pharma surges 5% after USFDA classifies Hyderabad facility as VAI

Business Standard

Natco Pharma stock was trading at 884.5, up 3.2 per cent compared to the previous session's close of 857.25 on the NSE

Natco Pharma Ltd.'s price crossed below 30Day SMA today

Alkem Laboratories Ltd.

18 Sep 2025

5495.00

-0.84%

Company Update

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Please find enclosed herewith the details of investor meetings scheduled to be held on 25th September, 2025, 26th September, 2025 and 30th September, 2025.

pdf

Natco Pharma Ltd.

18 Sep 2025

864.50

-2.23%

Company Update

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Natco''s Pharma Division located in Kothur, Hyderabad, India has now received Establishment Inspection Report (EIR) classifying the facility as Voluntary Action Indicated (VAI) from the U.S. Food and Drug Administration (FDA)

pdf

Lupin Ltd.

18 Sep 2025

2004.40

-2.49%

Lupin Gets US FDA Approval For Generic Lenalidomide Capsules

NDTV Profit

Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma, in combination with dexamethasone.

Lupin Ltd. is trading above its 150 day SMA of 1980.4

Lupin gets USFDA nod for generic cancer drug Lenalidomide capsules

Business Standard | 18 Sep 2025 1 more

Granules India Ltd.

18 Sep 2025

526.30

-3.15%

GRANULES INDIA

Accumulate: Granules India Ltd.

Target

Geojit BNP Paribas

We remain positive on Granules' long-term growth and profitability, supported by new product launches across geographies, a focus on backward integration, and rising market share. Entry into the CDMO segment via the Senn acquisition, along with higher-margin oncology filings, is expected to strengthen financials. Moreover, resolution of regulatory issues at the Gagilapur facility could act as a key re-rating catalyst. Hence, we maintain an Accumulate rating on the...

Granules India Ltd. has an average target of 615.75 from 4 brokers.

Mankind Pharma Ltd.

17 Sep 2025

2594.90

-2.47%

Mankind Pharma collaborates with OpenAI to build agile supply chains, research

Business Line

Mankind will integrate OpenAI Enterprise across multiple functions, including field force enablement, digital marketing, research and development (R&D), manufacturing, and medical affairs

Mankind Pharma Ltd. has an average target of 2840.50 from 2 brokers.

Is Nifty Pharma worth buying?

324 Votes:

Buy 79.32%

Sell 11.73%

Hold 8.95%

Nifty Pharma PB	4.8
Nifty Pharma PE	32.5
Nifty Pharma DIV	0.7
Nifty Pharma EPS	689.2